Background:　Several　studies　have　indicated　possible　associations　between　age　and　the　prognosis　of　breast　cancer　(BC),　but　limited　data　are　available　from　hospital-based　multicenter　studies　in　China.　This　study　aimed　to　explore　the　associations　between　age　at　initial　diagnosis　of　BC　and　the　risk　of　recurrence　or　metastasis　among　Chinese　women　with　newly　diagnosed　advanced　breast　cancer　(ABC)　and　provide　treatment　decision　support　for　BC　patients　of　different　ages　to　medical　workers.　Methods:　The　medical　records　of　patients　newly　diagnosed　with　ABC　were　obtained　from　21　hospitals　in　seven　geographic　regions　in　China　from　2012　to　2014.　Patients＇　general　information,　clinicopathological　features　at　first　diagnosis,　treatment　information,　and　prognosis　were　retrospectively　collected　based　on　the　self-designed　case　report　form　(CRF).　Cox　proportional　hazards　regression　models　were　used　to　determine　hazard　ratios　(HR)　and　95%　confidence　intervals　(CI)　for　the　associations　between　age　groups　and　the　risk　of　recurrence　and　metastasis.　Results:　A　total　of　1,852　cases　were　included　in　the　final　analysis.　Age　at　initial　diagnosis　was　shown　to　be　significantly　related　to　hormone　receptor　status,　human　epidermal　growth　factor　receptor　2　(HER2)　status,　molecular　subtypes,　and　the　number　of　lymph　node　metastasis　(all　P＜0.05).　Patients　aged　＜35　years　were　more　likely　to　have　bone　metastasis　(45.6%).　Patients　aged　＞=　65　years　had　a　lower　percentage　of　receiving　surgery　(87.1%),　adjuvant　chemotherapy　(61.3%),　adjuvant　radiotherapy　(35.5%),　and　adjuvant　endocrine　therapy　(30.6%)　than　the　other　groups　(all　P＜0.05).　Compared　with　patients　aged　＜35　years,　the　risk　of　recurrence　or　metastasis　in　those　aged　55-64　years　was　significantly　higher　(HRage　55-64　=1.24,　95%　CI:　1.04-1.47),　and　the　risk　of　bone　metastasis　and　lung　metastasis　in　those　aged　35-14　years　was　lower　(HRbone　(metastasis)　=0.74,　95%　CI:　0.59-0.93;　HRlung　metastasis　=0.70,　95%　CI:　0.53-0.93).　After　adjusting　for　stage,　grade,　and　molecular　subtype,　surgery,　neoadjuvant　chemotherapy,　adjuvant　chemotherapy,　adjuvant　radiotherapy,　adjuvant　endocrine　therapy,　and　Family　history　of　BC,　patients　aged　35-44　years　still　had　a　significantly　reduced　risk　of　bone　metastasis　and　lung　metastasis　by　31%　and　52%,　respectively　(HRbone　metastasis　=0.69,　95%　CI:　0.48-0.98;　HRlung　metastasis　=0.48,　95%　CI:　0.31-0.74).　Conclusions:　Age　at　initial　diagnosis　is　related　to　the　clinicopathological　characteristics　and　treatment　pattern.　Although　the　risk　of　site-specific　metastasis　varies　by　age,　age　is　not　an　independent　factor　influencing　the　risk　of　total　recurrence　and　metastasis.　In　accordance　with　current　clinical　practice　guidelines　for　BC,　however,　precise　treatment　shall　be　chosen　personally　for　patients　whose　ages　at　initial　diagnosis　are　different.